Ambling toward patent cliff, flinty Pfizer boasts of pipeline
Pfizer delivered a low-key analyst day, offering no surprises as it advances toward a "cliff" of patent expirations on major products.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.